Abstract:
The styrene derivative of the present invention is characterized by comprising a compound represented by general formula (I), wherein at least one of R 1 , Rz, Ra, R 4 and R 5 is a carboxyl group, an alkyl group having 1 to 5 carbon atoms, a hydroxyalkyl group having 1 to 5 carbon atoms, a carboxyalkyl group having 2 to 6 carbon atoms, an alkoxycarbonyl group having 2 to 6 carbon atoms, an alkoxycarbonylalkyl group having 2 to 6 carbon atoms, or an aryl group and the remainders are each a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and R 6 is a sulfur atom or an oxygen atom. The styrene derivative has excellent capability of absorbing an ultraviolet ray having a wavelength form 290 nm, i.e., the shortest wavelength contained in sunrays reaching the surface of the earth, to 360 nm having an effect of causing the change In the plastics. The polystyrene derivative of the present invention is characterized by maintaining high water solubility through polymerization of said styrene derivative and causing no skin absorption, i.e., having high safety to the human body. Since the ultraviolet absorption wavelength region is the same as that which brings about a sunburn of the skin, which renders the polystyrene derivative suitable for use as an ultraviolet absorber. Further, according to the process for preparing the polystyrene derivative of the present invention, the polystyrene derivative can be purified in the stage of a monomer, which makes it possible to provide a polystyrene derivative having high quality and high stability.
Abstract:
Verbindungen der Formel I worin A, X₁, X₂, X₃, X₄, Y, Z und R₁-R₆ die in der Beschreibung angegebenen Bedeutungen haben, weisen wertvolle pharmazeutische Eigenschaften auf und sind insbesondere gegen Tumoren wirksam. Sie werden in an sich bekannter Weise hergestellt.
Abstract:
This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.
Abstract:
The present invention relates to chelator compounds for chelating metal ions. In particular, the present invention relates to (thio)semicarbazone compounds and (thio)hydrazone compounds, such as PpYeT and PpYaT, which are chelators for metal ions, including iron ions. Therapeutic use of such compounds and/or their metal ion complexes, includes methods for treating and inhibiting HIV-1 replication, particularly in HIV-1 infected cells.
Abstract:
The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
Abstract:
The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
Abstract:
This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.
Abstract:
The present invention provides a novel class of compounds that disrupt the parasitic infectious life cycle and serve as promising agents for anti-parasitic therapy.